Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). - Suppr | 超能文献

Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).

作者信息

Sanders J, Crawford B, Gibson J, Joy Ho P, Iland H, Joshua D

出版信息

Int J Lab Hematol. 2007 Oct;29(5):395-7. doi: 10.1111/j.1365-2257.2006.00860.x.

DOI:10.1111/j.1365-2257.2006.00860.x

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).

Int J Lab Hematol. 2007 Oct;29(5):395-7. doi: 10.1111/j.1365-2257.2006.00860.x.

2

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.梅奥诊所关于双膦酸盐在多发性骨髓瘤中应用的共识声明。

Mayo Clin Proc. 2006 Aug;81(8):1047-53. doi: 10.4065/81.8.1047.

3

Atypical insufficiency type femoral stress fractures in patient on bisphosphonates.使用双膦酸盐类药物的患者发生的非典型 insufficiency 型股骨应力性骨折

Med Health R I. 2012 Feb;95(2):61-2.

4

Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.颅骨底骨髓炎和多发性骨髓瘤中双磷酸盐的使用：两例报告及文献复习。

Laryngoscope. 2010;120 Suppl 4:S175. doi: 10.1002/lary.21639.

5

[Advances in the field of osteoporosis].[骨质疏松领域的进展]

Rev Prat. 2007 Oct 15;57(15):1629-31.

6

Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.维生素D受体基因型与地中海贫血所致骨质疏松症患者对唑来膦酸治疗的反应

Ann Hematol. 2008 Nov;87(11):947-8. doi: 10.1007/s00277-008-0497-5. Epub 2008 Apr 29.

7

Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.中间型地中海贫血所致骨质疏松患者，尽管唑来膦酸使骨矿物质密度有所改善，但促红细胞生成活性仍持续增加。

Acta Haematol. 2008;119(1):40-4. doi: 10.1159/000114869. Epub 2008 Feb 5.

8

[Osteoporosis--new therapeutic possibilities. The Danish Bone Society].[骨质疏松症——新的治疗可能性。丹麦骨科学会]

Ugeskr Laeger. 2008 Mar 17;170(12):1043.

9

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.每年静脉注射一次唑来膦酸用于治疗绝经后骨质疏松症。

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

10

Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.唑来膦酸：新适应症。对绝经后骨质疏松症无治疗优势。

Prescrire Int. 2008 Aug;17(96):143.

引用本文的文献

1

Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.唑来膦酸治疗多发性骨髓瘤患者高剂量化疗和干细胞移植的随机临床试验。

Curr Oncol. 2013 Feb;20(1):e13-20. doi: 10.3747/co.20.1055.

2

The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.双膦酸盐在多发性骨髓瘤中的作用：机制、副作用及未来。

Oncologist. 2011;16(5):651-62. doi: 10.1634/theoncologist.2010-0225. Epub 2011 Apr 14.

3

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.唑来膦酸对比氯膦酸在多发性骨髓瘤（MRC Myeloma IX）一线治疗中的应用：一项随机对照试验。

Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.